SCHEMBL7103725

SCHEMBL7103725

Cc1ccc(S(=O)(=O)N(c2cccc(N(C=O)Nc3cc(Cl)cc(Cl)c3)c2)S(=O)(=O)c2ccc(C)cc2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPRC P08575 1/20 0.42
F2 P00734 1/20 0.41
LMNA P02545 3/20 0.38
CA12 O43570 1/20 0.37
CA9 Q16790 1/20 0.37
PGR P06401 1/20 0.36
MAPT P10636 5/20 0.36
ALDH1A1 P00352 3/20 0.36
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
C5AR1 P21730 1/20 0.35
NPSR1 Q6W5P4 2/20 0.35
USP2 O75604 1/20 0.35
MAPK1 P28482 1/20 0.35
CNR1 P21554 1/20 0.35
HTT P42858 1/20 0.35
MCOLN3 Q8TDD5 1/20 0.35
GPR55 Q9Y2T6 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7518536 0.93 TP53 (0.41) F2LMNAMAPTALDH1A1KDM4E
SCHEMBL7522385 0.89 S1PR1 (0.40) F2LMNAPGRMAPTALDH1A1
SCHEMBL7103877 0.78 S1PR1 (0.39)
SCHEMBL7514901 0.76 MAPT (0.55) LMNACA12CA9MAPTALDH1A1
SCHEMBL7101079 0.75 TP53 (0.44) PTPRCF2LMNAALDH1A1KDM4E
SCHEMBL7098960 0.74 TP53 (0.50) PTPRCF2LMNAALDH1A1KDM4E
SCHEMBL6836509 0.71 S1PR1 (0.33)
SCHEMBL7518541 0.70 ALDH1A1 (0.55) LMNAMAPTALDH1A1MEN1KMT2A
SCHEMBL7517997 0.69 S1PR1 (0.44) PTPRCLMNAPGRMAPTALDH1A1
SCHEMBL7512445 0.68 ALDH1A1 (0.53) LMNAMAPTALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020127605-A1 Bisubstituted carbocyclic cyclophilin binding compounds and their use GUILFORD PHARMACEUTICALS, INC. 2002-09-12 US claimed
EP-1339668-A2 BISUBSTITUTED CARBOCYCLIC CYCLOPHILIN BINDING COMPOUNDS AND THEIRUS GUILFORD PHARMACEUTICALS INC. (US) 2003-09-03 EP disclosed
US-20020127605-A1 Bisubstituted carbocyclic cyclophilin binding compounds and their use GUILFORD PHARMACEUTICALS, INC. 2002-09-12 US disclosed
WO-2002044126-A2 BISUBSTITUTED CARBOCYCLIC CYCLOPHILIN BINDING COMPOUNDS AND THEIRUS GUILFORD PHARMACEUTICALS INC. (US) 2002-06-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020127605-A1 Bisubstituted carbocyclic cyclophilin binding compounds and their use PPIG, PIN1, PPIH PTPRC 86/4885F2 1910/4885LMNA 4569/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.